Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, including its biobank of customer genetic samples, have been purchased by American biotechnology company Regeneron Pharmaceuticals for a cool $256 million, the highest bid submitted in the once-hot startup’s bankruptcy auction.

Regeneron said it will acquire 23andMe’s genomics service and its bank of 15 million customers’ personal and genetic data as part of the deal. The pharma giant said it plans to use the 23andMe customer data to help drug discovery, and that it will “prioritize the privacy, security, and ethical use of 23andMe’s customer data.”

Regeneron Pharmaceuticals on Monday said it would buy genetic testing company 23andMe, which filed for bankruptcy in March following a series of setbacks.